Assam CM hands over appointment letters to 400 Medical, Health Officers

400 Medical, Health Officers appointed in Assam

Assam Chief Minister Himanta Biswa Sarma on Wednesday distributed appointment letters to 400 health officers, asserting that his government is committed to creating employment opportunities for youths.

At an official function here, Sarma distributed the appointment letters among ‘Medical and Health Officers’, and said it marked a cumulative total of 1,20,359 recruitments provided to youths in the state.

“Taking a leap towards our goal of over 1.5 lakh government jobs, I am distributing appointment letters to 400 Medical and Health Officers. These officers will add muscle to our efforts of delivering quality healthcare to the last mile at the grassroots,” he said, news agency PTI reported.

In the last few years, delivering quality healthcare and providing jobs have been the key priorities of the Assam government, Sarma said.

“With these appointments, the aspirations of millions of people of getting better healthcare delivery and services will be fulfilled,” he said.

For more information, click on the link below:

400 Medical, Health Officers appointed in Assam

Powered by WPeMatico

Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

New Delhi: In a regulatory relief to the company, the Subject Expert Committee (SEC) under the Gastroenterology and Hepatology division of the Central Drugs Standard Control Organisation (CDSCO) has recommended the removal of a packaging and promotional condition earlier imposed on the fixed-dose combination (FDC) of Pantoprazole Sodium IP (Enteric coated pellets) 40 mg and Levosulpiride (SR tablets) 75 mg, marketed by Sun Pharma Laboratories Ltd.

The proposal was considered during the 07th SEC meeting held on 12th June 2025 at CDSCO headquarters in New Delhi. Sun Pharma referred to the condition imposed under Form 46 permission dated 27th January 2014, which stated that the FDC “shall be supplied in a Monocarton of 10 tablets per strip” and that “each pack, package insert and other promotional literature shall bear the statement: ‘Indicated for short term treatment of GERD in adult patients who do not respond to PPI alone.’”

After detailed deliberation, the SEC recommended relaxation of the packaging requirement. As per the committee’s conclusion, “The committee agreed for the removal of above said condition.”

However, the SEC maintained that the indication disclaimer must continue to be prominently displayed. It stated, “The firm should print ‘indicated for short term treatment of GERD in adult patients who do not respond to PPI alone’ on all packing materials including strip and outer carton.”

The FDC of Pantoprazole, a proton pump inhibitor (PPI), and Levosulpiride, a prokinetic agent, is indicated for the treatment of gastroesophageal reflux disease (GERD), particularly in patients who do not respond adequately to PPIs alone. The updated recommendation provides manufacturers with greater flexibility in packaging formats while ensuring that therapeutic indications are clearly communicated to prescribers and patients.

Powered by WPeMatico

Darzalex receives positive EMA Committee opinion for high-risk smouldering multiple myeloma: Janssen-Cilag International

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new indication for DARZALEX (daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. If approved, daratumumab could shift the treatment paradigm by becoming the approved therapy for this disease.

SMM is an asymptomatic intermediate disease state of multiple myeloma where abnormal cells can be detected in the bone marrow. The current standard of care (SOC) for SMM, even in high-risk cases, is active monitoring (or “Watch and Wait”) to track for signs of biochemical progression and/or end-organ damage. This means therapeutic intervention is only offered when the disease progresses.

“The positive recommendation from the CHMP marks an important step towards addressing the needs of people living with high-risk smouldering multiple myeloma,” said Ester in’t Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. “Early disease intervention with daratumumab has the potential to reduce the risk of progression to active multiple myeloma or death by 51 percent for patients with high-risk disease. Pending European Commission approval, patients and physicians will have an option to treat high-risk smouldering multiple myeloma, with the aim to intercept this complex blood cancer before it develops into active disease and importantly, before end-organ damage occurs.”

The CHMP recommendation is supported by data from the Phase 3 AQUILA study ( NCT03301220 ), evaluating the efficacy and safety of fixed-duration monotherapy daratumumab SC compared with active monitoring in those with high-risk SMM. Johnson & Johnson also submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of a new indication for daratumumab SC for the treatment of adult patients with high-risk SMM, based on the Phase 3 AQUILA data, on 8th November 2024. The first data from the study were previously presented at the 2024 American Society of Hematology (ASH) Annual Meeting and simultaneously published in the New England Journal of Medicine. Daratumumab is currently approved in nine indications for multiple myeloma, five of which are in the frontline setting.

“Daratumumab has become a foundational treatment across all stages of multiple myeloma, and we are on a mission to continue to evolve the treatment paradigm to reach those with high-risk smouldering multiple myeloma who may benefit from proactive earlier intervention,” said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine. “Today’s positive CHMP opinion marks positive scientific progress towards this goal and reinforces our vision of eliminating multiple myeloma.”

In August 2012, Janssen Biotech, Inc., a Johnson & Johnson company, and Genmab A/S entered a worldwide agreement, which granted Johnson & Johnson an exclusive licence to develop, manufacture and commercialise daratumumab. Since launch, daratumumab has become a foundational therapy in the treatment of multiple myeloma, having been used in the treatment of more than 618,000 patients worldwide. Daratumumab is a CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma. Daratumumab SC is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE drug delivery technology.

CD38 is a surface protein that is present in high numbers on multiple myeloma cells, regardless of the stage of disease. Daratumumab binds to CD38 and inhibits tumour cell growth causing myeloma cell death. Daratumumab may also have an effect on normal cells. Data across ten Phase 3 clinical trials, in both the frontline and relapsed settings, have shown that daratumumab-based regimens resulted in significant improvement in progression-free survival and/or overall survival.

Powered by WPeMatico

Face Wash vs Cleanser: Myths Busted for Sensitive Skin by Dr Aman Dua

In this video, Dr. Aman Dua, Renowned Dermatologist, Hair Transplant Surgeon, and Co-Founder & Managing Director at AK Clinics, breaks down the often confusing debate: Face Wash vs Cleanser – what’s right for your skin?

Dr. Dua addresses common myths and misconceptions, especially around sensitive skin. One frequently asked question she tackles is: “True or False – Sensitive skin should only be washed with water?” Dr. Dua explains why this approach may not be enough to effectively cleanse the skin, especially in polluted environments.

Another point of confusion she clears up is: “Is a cleanser the same as a face wash?” – a common dilemma for many skincare users. Dr. Dua highlights the differences in formulation, usage, and suitability based on individual skin types.

Whether you have oily, dry, or sensitive skin, understanding these differences can help you build a skincare routine that actually works. Watch the full video to discover how to choose the right product, when to use what, and how to care for your skin without overdoing it.

Powered by WPeMatico

Medical Bulletin 21/June/2025

Here are the top medical bulletins for the day:

Intermittent Fasting versus Calorie-Restricted Diets for Weight Loss: What Works Better?

Intermittent fasting diets appear to offer similar benefits to traditional calorie-restricted diets for weight loss and improving cardiometabolic health, according to a large analysis of clinical trial data published in The BMJ. The study also found that alternate day fasting may offer modest advantages over other intermittent fasting methods, though researchers emphasize the need for longer trials to confirm these results.

Researchers conducted a systematic review and network meta-analysis of 99 randomized clinical trials involving 6,582 adults with an average age of 45 and average BMI of 31. Nearly 90% of participants had existing health conditions. The trials, lasting from 3 to 52 weeks, compared various intermittent fasting strategies with calorie-restricted and unrestricted diets, assessing outcomes such as weight loss and cholesterol levels.

The analysis found that all intermittent fasting strategies and continuous calorie restriction led to small reductions in body weight compared to an unrestricted diet. Alternate day fasting was the only approach that showed a slight benefit over calorie restriction, with a mean additional weight loss of 1.29 kg. However, this did not meet the clinically significant threshold of 2 kg set by the authors.

Alternate day fasting was also associated with modest improvements in total and “bad” cholesterol compared to time-restricted eating, though no differences were found for blood sugar or “good” cholesterol levels.

The authors acknowledge limitations including short trial durations and varying quality, but highlight that this is one of the first reviews to compare all strategies in a comprehensive model. “The current evidence provides some indication that intermittent fasting diets have similar benefits to continuous energy restriction,” they conclude.

Reference: Semnani-Azad Z, Khan T A, Chiavaroli L, Chen V, Bhatt H A, Chen A et al. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials BMJ 2025; 389 :e082007 doi:10.1136/bmj-2024-082007

Addictive Screen Use May Be Linked to Poor Mental Health in Preteens: Study Finds

Addictive use of social media, mobile phones, and video games- but not overall screen time- is associated with worsening mental health and increased risk of suicidal thoughts and behaviors among preteens, according to a new study published in JAMA.

Concerns have grown in recent years about the effects of screen exposure on children and adolescents, especially amid rising rates of anxiety, depression, and suicidal behavior. This new study, involving nearly 4,300 children from the Adolescent Brain Cognitive Development Study, looked at signs of addictive behavior- such as compulsive use that interferes with daily life- and how those patterns evolved over four years starting at age 8.

The researchers tracked children’s use of social media, mobile phones, and video games, and assessed how their screen use aligned with behaviors commonly linked to addiction. These included statements like “I play video games so I can forget about my problems,” or “I feel the need to use social media apps more and more.” Based on responses, the team identified usage patterns and linked them to mental health data, including suicidal ideation and behaviors.

Children with high or increasingly addictive use of social media or mobile phones had two to three times greater risk of suicidal behaviors than their peers with low addictive use. Notably, total screen time alone showed no association with mental health outcomes.

“Policy efforts should move away from generic limits on screen time and instead focus on identifying and addressing addictive patterns of screen use,” said lead author Yunyu Xiao, PhD, of Weill Cornell Medicine.

Reference: Xiao Y, Meng Y, Brown TT, Keyes KM, Mann JJ. Addictive Screen Use Trajectories and Suicidal Behaviors, Suicidal Ideation, and Mental Health in US Youths. JAMA. Published online June 18, 2025. doi:10.1001/jama.2025.7829

Study Reveals How Obesity in Pregnancy Triggers Liver Disorders in Offspring

Children born to obese mothers may face an increased risk of developing metabolic disorders– even when they follow a healthy diet themselves. A new study published in Nature by researchers at the University of Bonn offers a compelling explanation: in obese mice, maternal obesity reprograms immune cells in the embryo’s liver, causing lasting disruptions to metabolic function in the offspring.

The study focused on Kupffer cells, a specialized type of macrophage that takes up permanent residence in the liver during embryonic development. These cells play a critical role not only in immune defense but also in regulating liver metabolism. “They instruct the surrounding liver cells on what to do,” explains Prof. Dr. Elvira Mass from the LIMES Institute at the University of Bonn. “In this way, they help ensure that the liver, as a central metabolic organ, performs its many tasks correctly.”

The researchers found that offspring of obese mouse mothers developed fatty liver disease shortly after birth—even when fed a normal diet. The team discovered that metabolic products from the mother activate a transcription factor in Kupffer cells during pregnancy, reprogramming them to send signals that promote fat accumulation in the liver.

To test whether this reprogramming could be reversed, the researchers genetically removed the transcription factor during pregnancy. As a result, the offspring did not develop fatty liver disease, offering a promising direction for future treatment strategies. Whether this pathway can be targeted with medication remains to be seen, and follow-up studies are underway.

“This switch is a so-called transcription factor. It controls which genes are active in Kupffer cells,” said Mass, emphasizing the precision of this molecular mechanism. The implications are far-reaching: early changes in liver programming may set the stage for lifelong health challenges.

Reference: Huang, H., Balzer, N.R., Seep, L. et al. Kupffer cell programming by maternal obesity triggers fatty liver disease. Nature (2025). https://doi.org/10.1038/s41586-025-09190-w

Powered by WPeMatico

Teaching experience before medical college’s recognition not valid for faculty appointment eligibility: HC

Shimla: While determining the issue of eligibility for appointment to the post of Assistant Professor, the Himachal Pradesh High Court recently clarified that teaching experience acquired before the recognition or establishment of a medical college under Section 10A of the Indian Medical Council Act, 1956, cannot be considered valid.

“The teaching experience thus would only as such be available to the petitioner post setting up of the College and could not have been there earlier though he might have been posted as such by the State at the initial stage for fulfilling the norms of the MCI by the State Government,” the HC Division bench Comprising Chief Justice G.S. Sandhawalia and Justice Ranjan Sharma held while considering the plea of a doctor in this regard.

The petitioner completed MBBS in 2000-2001 and later completed MS Surgery in July 2016 from Himachal Pradesh University. After this, he initially joined as a Medical Officer (Specialist) at Zonal Hospital, Mandi (H.P.) on August 16, 2016.

Later, he was transferred and designated as Senior Resident in the Department of Surgery with effect from December 8, 2016, after the establishment of Shri Lal Bahadur Shastri Government Medical College and Hospital (SLBS GMC).

However, it was only on May 31, 2017, when the college was formally recognised under Section 10A of the Indian Medical Council Act, 1956. In order to be appointed as an Assistant Professor, it is mandatory for the candidate to have three years of teaching experience after post-graduation in a recognized medical college.

Also Read: No relief on Bond service for Doctors: Himachal HC stays single bench order

On December 27, 2019, the Himachal Pradesh Public Service Commission issued an advertisement and invited applications for two posts of Assistant Professor in General Surgery. In this case, the cut-off date for eligibility was fixed as January 16, 2020. When the petitioner applied for the post, he got an NOC on January 9, 2020, and his name was forwarded by the Health Department for consideration. However, the NOC was kept in suspension on February 24, 2020, and was later withdrawn on August 11, 2020, based on the grounds that the petitioner doctor did not have the requisite three years of teaching experience as of the cut-off date.

Aggrieved by this, the petitioner filed a plea in the High Court seeking direction to appoint him as an Assistant Professor. However, the single judge bench denied the same, and thereafter the petitioner approached the Division Bench of the High Court.

The doctor argued that he had been designated as a Senior Resident on December 8, 2016, and thereafter, he had continuously rendered service in that capacity in the Department of Surgery at SLBS Government Medical College. He also submitted that his teaching experience should be counted from 08.12.2016, which would make him eligible for the post of Assistant Professor as per the recruitment rules on the cut-off date of January 16, 2020. 

Therefore, referring to the experience certificate and the NOC, the doctor argued that the competent authority had verified and certified his eligibility, and his name was duly forwarded to the Himachal Pradesh Public Service Commission for selection. It was also argued that similarly situated candidates were also granted the benefit of experience from the same date.

On the other hand, the State Government authorities argued that as per the statutory Recruitment Rules, the petitioner was required to possess three years of teaching experience after completing post-graduation in the concerned speciality from a recognised medical college. It was also argued that the SLBS Government Medical College was recognised on May 31, 2017, and therefore, any experience before this date could not be counted for eligibility.

Pointing out that the cut-off date for eligibility was mentioned as January 16, 2020, in the advertisement, the authorities argued that the petitioner did not meet the experience requirement on that date. It was also submitted that merely participating in the selection process or being recommended provisionally did not create any right to appointment in the absence of fulfilling the essential eligibility conditions.

Apart from this, it was also submitted by the authorities that the petitioner’s NOC had been withdrawn after proper scrutiny, as he did not possess the requisite three years’ teaching experience as per the rules.

While considering the matter, the HC bench observed that the eligibility criteria mentioned in the advertisement required a minimum of three years of teaching experience after completing post-graduation from a recognised medical college.

The bench noted that the same eligibility criteria were mentioned in the Recruitment Rules of 1999 as well. It was also observed that the college where the petitioner was posted was officially recognised only on May 31, 2017 and therefore, the petitioner’s experience before that date could not be counted as valid for determining eligibility.

“…the requirement is three years teaching experience as Lecturer/Resident after doing the Post Graduation with the concerned specialty which was not available with the petitioner inasmuch as the said College was set up on 31.05.2017 in terms of Section 10A of the Indian Medical Council Act, 1956. The teaching experience thus would only as such be available to the petitioner post setting up of the College and could not have been there earlier though he might have been posted as such by the State at the initial stage for fulfilling the norms of the MCI by the State Government,” observed the Court.

“It is a settled principle that the eligibility has to be seen at the time of the cut off date and is sacrosanct as such and in such circumstances, the reasons as such for the State to withdraw the NOC granted does not fault in any manner. Merely because he has been designated and working as a Senior Resident in the College since the date of experience could not be treated as 08.12.2016 as the first batch of the annual intake of the M.B.B.S students only took place from the Academic Year 2017-18 and the three years teaching experience is to be calculated from that date. The petitioner thus did not have the requisite three years experience as on 16.01.2020,” the Court further noted. 

“Merely because he is qualified as such and the strength of provisional concession given on an earlier account would as such not make it his legal right as he had only right of consideration which was subject to the terms of eligibility as per the terms of the advertisement,” the Division bench mentioned in the order.

The Court observed that it was a settled principle that the advertisement had a force of law and it bound both the petitioner and the State. Perusing the conditions mentioned in the advertisement regarding the requirement of NOC, the bench noted, “Thus, in the absence of the requisite NOC as a regular service candidate he was not liable to be interviewed and the NOC having been withdrawn for valid reasons as per the provisions of the Rules could not be said to be an arbitrary decision of the State, which can be judicially reviewed and reversed, in any manner.”

Dismissing the petitioer’s appeal, the Court concluded,

“Resultantly, we have come to the conclusion that the petitioner not being eligible as per the statutory rules which provides the necessary qualifications and the minimum qualifications for direct recruits and the minimum educational requirements and the requisite teaching experience which would necessarily be only when the concerned intake of the students would come and not prior to that. Resultantly, the reasoning which has been arrived at by the learned Single Judge cannot be faulted in any manner….In such circumstances, we do not find any plausible reason as such to interfere with the well reasoned order passed by the learned Single Judge dismissing the writ petition filed by the appellant.”

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/himachal-pradesh-hc-order-291661.pdf

Also Read: ‘Doctors are not slaves’, State cannot force service if bond is paid: HC

Powered by WPeMatico

From blood sugar to brain relief: GLP-1 therapy linked to lower migraine frequency

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

Powered by WPeMatico

Research uncovers link between nighttime heart rhythm and future health conditions

A study conducted at the Department of Neurology, Inselspital, the University Hospital of Bern, analyzed 4,170 individuals over an observation period of 13,217 person-years. It found that heart rate variability (HRV) during sleep can serve as a powerful early warning sign of future health conditions, including stroke, depression, and cognitive dysfunction.

Powered by WPeMatico

Why acute and chronic pain are so different—and what might make pain last

A new study reveals that when we experience short-term (acute) pain, the brain has a built‑in way to dial down pain signals—like pressing the brakes—to keep them from going into overdrive. But in long‑term (chronic) pain, this braking system fails, and the pain signals just keep firing. This discovery helps explain why some pain goes away while other pain lingers, and it opens the door to new treatments that could stop pain from becoming chronic in the first place.

Powered by WPeMatico

Autism inpatient collection releases genetic, phenotypic data for more than 1,500 children with autism

The Simons Foundation Autism Research Initiative (SFARI) has released phenotypic and genetic data from the Autism Inpatient Collection (AIC), a cohort of more than 1,500 youth participants ages 4 to 20 years old who were hospitalized in one of six child psychiatry units in the United States. The AIC aimed to engage these individuals, many of whom meet recently proposed criteria for “profound autism” (autism characterized by intellectual disability or minimal language that requires high levels of supervision and support) as they are substantially underrepresented in datasets derived from outpatient or community settings.

Powered by WPeMatico